The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-02-07

AUTHORS

Yoshimi Ishii, Naoto Tomita, Ukihide Tateishi, Yasufumi Ishiyama, Eri Yamamoto, Yukako Hattori, Maki Hagihara, Etsuko Yamazaki, Yoshiaki Ishigatsubo

ABSTRACT

[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (ΔSUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated ΔSUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the ΔSUVmax for disease progression. The 3-year progression-free survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 91 and 25 %, respectively (P < 0.001). The 4-year overall survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 100 and 83 %, respectively (P = 0.046). The ΔSUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients. More... »

PAGES

880

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0

DOI

http://dx.doi.org/10.1007/s12032-014-0880-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014433754

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24504845


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishii", 
        "givenName": "Yoshimi", 
        "id": "sg:person.0665120613.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Naoto", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tateishi", 
        "givenName": "Ukihide", 
        "id": "sg:person.0742073556.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishiyama", 
        "givenName": "Yasufumi", 
        "id": "sg:person.01362612150.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Eri", 
        "id": "sg:person.01342505175.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342505175.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Yukako", 
        "id": "sg:person.01107773320.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hagihara", 
        "givenName": "Maki", 
        "id": "sg:person.0663130331.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamazaki", 
        "givenName": "Etsuko", 
        "id": "sg:person.0731243531.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731243531.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-012-1602-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016010275", 
          "https://doi.org/10.1007/s00277-012-1602-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-013-2435-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025772213", 
          "https://doi.org/10.1007/s00259-013-2435-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-012-1640-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043703793", 
          "https://doi.org/10.1007/s00277-012-1640-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-012-2320-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003249840", 
          "https://doi.org/10.1007/s00259-012-2320-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-02-07", 
    "datePublishedReg": "2014-02-07", 
    "description": "Abstract[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (\u0394SUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated \u0394SUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the \u0394SUVmax for disease progression. The 3-year progression-free survival rate of patients with \u0394SUVmax \u226583 and <83\u00a0% was found to be 91 and 25\u00a0%, respectively (P\u00a0<\u00a00.001). The 4-year overall survival rate of patients with \u0394SUVmax \u226583 and <83\u00a0% was found to be 100 and 83\u00a0%, respectively (P\u00a0=\u00a00.046). The \u0394SUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-014-0880-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "positron emission tomography", 
      "maximum standardized uptake value", 
      "cell lymphoma patients", 
      "standardized uptake value", 
      "CHOP therapy", 
      "DLBCL patients", 
      "disease progression", 
      "lymphoma patients", 
      "uptake value", 
      "survival rate", 
      "progression-free survival rates", 
      "positron emission tomography scan", 
      "overall survival rate", 
      "emission tomography scan", 
      "optimal cutoff value", 
      "characteristic curve analysis", 
      "initial therapy", 
      "primary staging", 
      "tomography scan", 
      "treatment outcomes", 
      "PET scans", 
      "patients", 
      "cutoff value", 
      "emission tomography", 
      "therapy", 
      "curve analysis", 
      "\u0394SUVmax", 
      "progression", 
      "survival", 
      "tomography", 
      "scans", 
      "diffuse", 
      "staging", 
      "outcomes", 
      "rate", 
      "reduction", 
      "rate of reduction", 
      "evaluation", 
      "values", 
      "initial", 
      "analysis", 
      "prediction", 
      "Receiver observation characteristic curve analysis", 
      "observation characteristic curve analysis"
    ], 
    "name": "The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients", 
    "pagination": "880", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014433754"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-014-0880-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24504845"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-014-0880-0", 
      "https://app.dimensions.ai/details/publication/pub.1014433754"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_629.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-014-0880-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0880-0'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      22 PREDICATES      98 URIs      86 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-014-0880-0 schema:about N03a3d55945f746b29297507c047990cf
2 N14e3b2c3a47445b5848b40747921a6c7
3 N1aec2e12ba0544af800163977123e7c1
4 N1aee2f89eb064a098ce3926361dde823
5 N27558b29cd8e4e46b9a4db87a876e10e
6 N2aac45acc1fd4f5386d30ad177273865
7 N2ada330c57b34e7d8dc3efff805f020c
8 N400b3d34f0e34bf28488b0042fa6f61c
9 N50df437ea9654931bf333e42bbb8f4d8
10 N51841735d3f64aa89648247d852d1d51
11 N671cd12e82824a4bb780040b323e0a53
12 N6864cbc7b9aa4f94934197a715efb482
13 N78ee74ae6bcc45d4877f888cf48850d3
14 N7d92763214fc44dd8f51f630918abcd8
15 N83d165dcf4374abb951a477d847c8435
16 N8af2bfd39500440081d6b8820bef1253
17 N94d1196d2c2b420cb3319acd31ceac15
18 Nc0fa87b479244f4998bc4994fc21d0d4
19 Nd6b4b0373a954b11b26f49e6e03b8458
20 Ne2057389f1d949a7b09aeed646b409b4
21 Nea5a2cd02f784168a667af644a9e77a0
22 Nebfc86f738094854b338e7242667a96b
23 Nf28c68fb55194bb8991537f235578358
24 Nf715a6097ec84c60b5b00548895aa066
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author Nc5e57bca75fe41d880065805ef887f0a
28 schema:citation sg:pub.10.1007/s00259-012-2320-8
29 sg:pub.10.1007/s00259-013-2435-6
30 sg:pub.10.1007/s00277-012-1602-3
31 sg:pub.10.1007/s00277-012-1640-x
32 schema:datePublished 2014-02-07
33 schema:datePublishedReg 2014-02-07
34 schema:description Abstract[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (ΔSUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated ΔSUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the ΔSUVmax for disease progression. The 3-year progression-free survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 91 and 25 %, respectively (P < 0.001). The 4-year overall survival rate of patients with ΔSUVmax ≥83 and <83 % was found to be 100 and 83 %, respectively (P = 0.046). The ΔSUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N90bfd5a0c79c4ef8a48d2b83b7ec0a1c
39 Ne13f748af200450b80619a401e15e626
40 sg:journal.1094524
41 schema:keywords CHOP therapy
42 DLBCL patients
43 PET scans
44 Receiver observation characteristic curve analysis
45 analysis
46 cell lymphoma patients
47 characteristic curve analysis
48 curve analysis
49 cutoff value
50 diffuse
51 disease progression
52 emission tomography
53 emission tomography scan
54 evaluation
55 initial
56 initial therapy
57 lymphoma patients
58 maximum standardized uptake value
59 observation characteristic curve analysis
60 optimal cutoff value
61 outcomes
62 overall survival rate
63 patients
64 positron emission tomography
65 positron emission tomography scan
66 prediction
67 primary staging
68 progression
69 progression-free survival rates
70 rate
71 rate of reduction
72 reduction
73 scans
74 staging
75 standardized uptake value
76 survival
77 survival rate
78 therapy
79 tomography
80 tomography scan
81 treatment outcomes
82 uptake value
83 values
84 ΔSUVmax
85 schema:name The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients
86 schema:pagination 880
87 schema:productId N4e2cd1033e8c4725851db860e779363e
88 Na3202e857b7447d28f0513db79eafb07
89 Ncac8e0e87eb647d3bd60fd6e21c9503c
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014433754
91 https://doi.org/10.1007/s12032-014-0880-0
92 schema:sdDatePublished 2021-11-01T18:22
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher N65f94bbc8ca348cca9d62f1ba9120596
95 schema:url https://doi.org/10.1007/s12032-014-0880-0
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N01bec49f7b73428598ca64b422af1159 rdf:first sg:person.01107773320.39
100 rdf:rest N6b9a71ae9f1c451e842f7091961456d6
101 N03a3d55945f746b29297507c047990cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Retrospective Studies
103 rdf:type schema:DefinedTerm
104 N14e3b2c3a47445b5848b40747921a6c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Doxorubicin
106 rdf:type schema:DefinedTerm
107 N1aec2e12ba0544af800163977123e7c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cyclophosphamide
109 rdf:type schema:DefinedTerm
110 N1aee2f89eb064a098ce3926361dde823 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Lymphoma, Large B-Cell, Diffuse
112 rdf:type schema:DefinedTerm
113 N27558b29cd8e4e46b9a4db87a876e10e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Vincristine
115 rdf:type schema:DefinedTerm
116 N2aac45acc1fd4f5386d30ad177273865 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prednisolone
118 rdf:type schema:DefinedTerm
119 N2ada330c57b34e7d8dc3efff805f020c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N349c079955214a33a5992e74214701b5 rdf:first sg:person.01125133646.44
123 rdf:rest rdf:nil
124 N400b3d34f0e34bf28488b0042fa6f61c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Disease Progression
126 rdf:type schema:DefinedTerm
127 N4b5c7a6aac9246668b2a3f4c71d5ed5b rdf:first sg:person.01155656464.01
128 rdf:rest N82dc986f4ae145da8ae72ec0c36ae11f
129 N4e2cd1033e8c4725851db860e779363e schema:name doi
130 schema:value 10.1007/s12032-014-0880-0
131 rdf:type schema:PropertyValue
132 N50df437ea9654931bf333e42bbb8f4d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N51841735d3f64aa89648247d852d1d51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged
137 rdf:type schema:DefinedTerm
138 N65f94bbc8ca348cca9d62f1ba9120596 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N671cd12e82824a4bb780040b323e0a53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Follow-Up Studies
142 rdf:type schema:DefinedTerm
143 N6864cbc7b9aa4f94934197a715efb482 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Positron-Emission Tomography
145 rdf:type schema:DefinedTerm
146 N6b9a71ae9f1c451e842f7091961456d6 rdf:first sg:person.0663130331.38
147 rdf:rest N8c8cd46c3ede4d5eaea3df9519f5c649
148 N78ee74ae6bcc45d4877f888cf48850d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Female
150 rdf:type schema:DefinedTerm
151 N7d92763214fc44dd8f51f630918abcd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Prognosis
153 rdf:type schema:DefinedTerm
154 N82dc986f4ae145da8ae72ec0c36ae11f rdf:first sg:person.0742073556.08
155 rdf:rest N8fb7596571d24f4c9e850b52f1fa2ee3
156 N83d165dcf4374abb951a477d847c8435 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Antineoplastic Combined Chemotherapy Protocols
158 rdf:type schema:DefinedTerm
159 N8af2bfd39500440081d6b8820bef1253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Aged, 80 and over
161 rdf:type schema:DefinedTerm
162 N8c8cd46c3ede4d5eaea3df9519f5c649 rdf:first sg:person.0731243531.94
163 rdf:rest N349c079955214a33a5992e74214701b5
164 N8fb7596571d24f4c9e850b52f1fa2ee3 rdf:first sg:person.01362612150.73
165 rdf:rest N948037bb72e44cc489b28e8629695989
166 N90bfd5a0c79c4ef8a48d2b83b7ec0a1c schema:volumeNumber 31
167 rdf:type schema:PublicationVolume
168 N948037bb72e44cc489b28e8629695989 rdf:first sg:person.01342505175.15
169 rdf:rest N01bec49f7b73428598ca64b422af1159
170 N94d1196d2c2b420cb3319acd31ceac15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Fluorodeoxyglucose F18
172 rdf:type schema:DefinedTerm
173 Na3202e857b7447d28f0513db79eafb07 schema:name dimensions_id
174 schema:value pub.1014433754
175 rdf:type schema:PropertyValue
176 Nc0fa87b479244f4998bc4994fc21d0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Survival Rate
178 rdf:type schema:DefinedTerm
179 Nc5e57bca75fe41d880065805ef887f0a rdf:first sg:person.0665120613.58
180 rdf:rest N4b5c7a6aac9246668b2a3f4c71d5ed5b
181 Ncac8e0e87eb647d3bd60fd6e21c9503c schema:name pubmed_id
182 schema:value 24504845
183 rdf:type schema:PropertyValue
184 Nd6b4b0373a954b11b26f49e6e03b8458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Rituximab
186 rdf:type schema:DefinedTerm
187 Ne13f748af200450b80619a401e15e626 schema:issueNumber 3
188 rdf:type schema:PublicationIssue
189 Ne2057389f1d949a7b09aeed646b409b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Male
191 rdf:type schema:DefinedTerm
192 Nea5a2cd02f784168a667af644a9e77a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Adult
194 rdf:type schema:DefinedTerm
195 Nebfc86f738094854b338e7242667a96b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Neoplasm Staging
197 rdf:type schema:DefinedTerm
198 Nf28c68fb55194bb8991537f235578358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Antibodies, Monoclonal, Murine-Derived
200 rdf:type schema:DefinedTerm
201 Nf715a6097ec84c60b5b00548895aa066 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Radiopharmaceuticals
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
208 schema:name Clinical Sciences
209 rdf:type schema:DefinedTerm
210 sg:journal.1094524 schema:issn 1357-0560
211 1559-131X
212 schema:name Medical Oncology
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.01107773320.39 schema:affiliation grid-institutes:grid.268441.d
216 schema:familyName Hattori
217 schema:givenName Yukako
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39
219 rdf:type schema:Person
220 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
221 schema:familyName Ishigatsubo
222 schema:givenName Yoshiaki
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
224 rdf:type schema:Person
225 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.268441.d
226 schema:familyName Tomita
227 schema:givenName Naoto
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
229 rdf:type schema:Person
230 sg:person.01342505175.15 schema:affiliation grid-institutes:grid.268441.d
231 schema:familyName Yamamoto
232 schema:givenName Eri
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342505175.15
234 rdf:type schema:Person
235 sg:person.01362612150.73 schema:affiliation grid-institutes:grid.268441.d
236 schema:familyName Ishiyama
237 schema:givenName Yasufumi
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73
239 rdf:type schema:Person
240 sg:person.0663130331.38 schema:affiliation grid-institutes:grid.268441.d
241 schema:familyName Hagihara
242 schema:givenName Maki
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663130331.38
244 rdf:type schema:Person
245 sg:person.0665120613.58 schema:affiliation grid-institutes:grid.268441.d
246 schema:familyName Ishii
247 schema:givenName Yoshimi
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665120613.58
249 rdf:type schema:Person
250 sg:person.0731243531.94 schema:affiliation grid-institutes:grid.268441.d
251 schema:familyName Yamazaki
252 schema:givenName Etsuko
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731243531.94
254 rdf:type schema:Person
255 sg:person.0742073556.08 schema:affiliation grid-institutes:grid.268441.d
256 schema:familyName Tateishi
257 schema:givenName Ukihide
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08
259 rdf:type schema:Person
260 sg:pub.10.1007/s00259-012-2320-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003249840
261 https://doi.org/10.1007/s00259-012-2320-8
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s00259-013-2435-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025772213
264 https://doi.org/10.1007/s00259-013-2435-6
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s00277-012-1602-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016010275
267 https://doi.org/10.1007/s00277-012-1602-3
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/s00277-012-1640-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043703793
270 https://doi.org/10.1007/s00277-012-1640-x
271 rdf:type schema:CreativeWork
272 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan
273 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
274 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, 236-0004, Yokohama, Japan
275 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...